Teva Announces Launch of Generic Gleevec® Tablets in the United States
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Mizuho Securities Cuts Price Target on Teva Pharma (TEVA) Following 2Q Beat
August 8, 2016 6:53 AM EDTMizuho Securities maintained a Buy rating on Teva Pharma (NYSE: TEVA), and cut the price target to $70.00 (from $75.00), following the company's 2Q earnings report. TEVA reported revenue of $5.0B and $1.25 EPS, vs. $4.88B and $1.20 consensus and management's recent guidance of $4.9- $5.0B and... More
Teva (TEVA): Soft 2Q Underscores Need For Actavis - Piper Jaffray
August 5, 2016 9:03 AM EDTPiper Jaffray analyst David Amsellem bumped his price target on Teva Pharma (NYSE: TEVA) to $57.00 (from $55.00) but maintained a Neutral rating following Q2 results.
Amsellem commented, "Teva reported 2Q16 non-GAAP diluted EPS of $1.25 on revenue of $5.04B; recall that the company pre-announced... More
